Login Register
Life Science Training Institute
  • WEBINARS/eLEARNING
    • Live Courses/Webinars
    • On-Demand Courses/Webinars
    • By Category
      • Clinical Trials (GCP)
      • Manufacturing
      • Medical Devices
      • Regulatory
      • R&D
      • Leadership & Training
    • eLearning
      • Clinical Pathways
      • DIGR-ACT: Critical Thinking Skills for Clinical Trials
    • LSTI Learning Library
    • Training Voucher Packages
    • Checkout
  • Custom Training
    • Live Training
    • Elearning Solutions
    • LSTI Corporate Learning Library
    • CRA Academy
  • Articles & Resources
  • About LSTI
    • LSTI Leadership
    • LSTI Instructors
    • Contact Us
    • Connect with LSTI
    • Frequently Asked Questions
  • Connect
  • WEBINARS/eLEARNING
    • Live Courses/Webinars
    • On-Demand Courses/Webinars
    • By Category
      • Clinical Trials (GCP)
      • Manufacturing
      • Medical Devices
      • Regulatory
      • R&D
      • Leadership & Training
    • eLearning
      • Clinical Pathways
      • DIGR-ACT: Critical Thinking Skills for Clinical Trials
    • LSTI Learning Library
    • Training Voucher Packages
    • Checkout
  • Custom Training
    • Live Training
    • Elearning Solutions
    • LSTI Corporate Learning Library
    • CRA Academy
  • Articles & Resources
  • About LSTI
    • LSTI Leadership
    • LSTI Instructors
    • Contact Us
    • Connect with LSTI
    • Frequently Asked Questions
  • Connect
What To Expect From The FDA During (And After) COVID-19

During a recent Halloran Virtual Town Hall meeting, a panel of experts to share what they are seeing in terms of regulatory activity, as some cases are receiving expedited feedback, while others are experiencing delays in reviews and receipt of commentary from the FDA. This article presents some key insights from the panel’s experience conducting regulatory activities during the pandemic.

Posted in: Clinical, FDA, Manufacturing,
Tags: CBER, CDER, CDHR, COVID-19, FDA,
Understanding 2019 FDA Enforcement Trends — And What They Mean For 2020

The FDA conducted a total of 18,034 inspections in FY2019, off which 6,434 were inspections of biologics, medical device, or drug companies. Those inspections resulted in the issuance of 15,015 warning letters, a slight increase over 2018. The FDA also increased its import alerts, publishing 98 in 2019. This corresponded with a decrease in injunctions and seizures, showing the FDA’s preference for earlier preventive measures over later involvement.

Posted in: FDA, Manufacturing,
Tags: FDA, form 483, inspections, warning letters,
U.S. Sites Play Surprise Starring Role In FDA’s Drug GMP Warning Letter Report

Fiscal year 2019 was a fascinating year for drug GMP warning letters in the diversity of topics addressed, depth of focus, and trends in enforcement actions. This article presents a comprehensive summary of the drug GMP warning letters issued in FY2019, including an evaluation of trends since FY2013.

Posted in: FDA, Manufacturing,
Tags: GMP, GMP compliant, inspections, warning letters,
FDA’s Drug Shortages Root Cause Report: Does It Miss The Mark?

At the behest of Congress, an inter-agency Drug Shortage Task Force, led by the FDA, recently published the “Drug Shortages: Root Causes and Potential Solutions” report. The very first root causes listed in the report are “economic forces,” indicating their undoubted primacy in the Task Force’s overall assumption as to their influence on drug shortages.

Posted in: FDA, Manufacturing,
Tags: Drug Shortage Task Force, drug shortages, medicines, prescription medication,
Pharmacy Compounding Vs. Manufacturing For Clinical Studies: The Regulatory Perspective

FDA requirements and compendial standards for pharmacy compounding and outsourcing continue to evolve, and the FDA has different requirements for products prepared through pharmacy compounding practices as compared to those manufactured for use in clinical studies.

Posted in: Clinical, FDA, Manufacturing,
Tags: compound sterile products, drug products, IND, pharmacy compounding,
Are You Prepared For Impending Changes To U.S. Biologics & Biosimilars Law?

Sponsors for insulins and other protein products originally submitted for premarket review under an NDA may be anticipating the arrival of March 23, 2020 with trepidation. On that date, the BPCIA requires that those NDA-approved products will be deemed to have a BLA approval instead of an NDA approval.

Posted in: FDA, Manufacturing,
Tags: biologics license approval, BLA, NDA, new drug application,
An Analysis Of The FDA’s Drug Shortages Root Cause Report

In Oct. 2019, the FDA’s Drug Shortage Task Force published a report that identified root causes of drug shortages across the U.S. healthcare system and made recommendations for effectively resolving those underlying issues. This article summarizes the report’s findings and discusses potential next steps the FDA may take.

Posted in: FDA, Manufacturing,
Tags: drug manufacturing, drug market, drug shortage crisis, drug shortages, supply chain,
Pediatric clinical trials
Pediatric Oncology Trials Under FDARA Section 504 — How To Prepare

Although the development of cancer drugs for children is riddled with challenges, the requirements in Section 504 of the FDA Reauthorization Act of 2017 (FDARA) represent a significant paradigm shift in pediatric oncology. Effective in August 2020, the act also ended an existing exemption for oncology drugs with orphan status and stipulated numerous statutory requirements for the agency itself.

Posted in: Clinical, FDA,
Tags: children, FDARA, oncology, pediatric, pediatric drug development, section 504,
FDA FY2019 Drug Inspection Observations And Trends

This article presents the most recent publication of GMP drug inspection data from CDER, published November 15, 2019 and addressing drug inspections conducted in FY2019. We’ll also take a look at seven years’ worth of trends in drug GMP inspections.

Posted in: FDA, Manufacturing,
Tags: drug inspections, form 483, GMP inspections,
Increase In Drug Approvals, Priority Reviews Points To Bright Future For CMO Industry

New drug approvals are on the way up, as the FDA approved 11 percent more innovator therapies in 2018 compared to the previous year, spelling good news for both marketing authorization holders (MAHs) and CMOs. Data also shows that small- and mid-cap pharma companies are increasingly turning to outsourcers to manufacture newly approved drugs.

Posted in: FDA, Manufacturing,
  • 1
  • 2
  • 3
  • …
  • 10
  • Next

Upcoming Live Courses

  • China GCP 2020: Understanding and Implementing New Compliance Requirements
  • How to Prepare for FDA Guidance on Computer Software Assurance (CSA) in 2021 – A Two Part Primer
  • It is Finally Here! Update to the ISO Medical Device GCP Standard: ISO 14155:2020
  • Preparing for Changes to ICH GCP E6(R3) and ICH E8(R1) – Readying for Risk Mitigation

Product categories

  • Coronavirus / COVID-19
  • Uncategorized
  • Clinical Trials (GCP Training)
  • Introductory Pharma Courses
  • IT & Data Integrity for Pharma
  • Leadership & Training
  • Live Webinars
  • Manufacturing (GMP)
  • Medical Device Training
  • On-Demand Courses
  • Quality
  • Regulatory & Compliance
  • Research & Development
  • Special Packages

About Us

The Life Science Training Institute helps pharma, biotech, and medical device companies build knowledgeable, compliant workforces by providing training from drug discovery through commercialization. We are dedicated to advancing careers of those working to develop new therapies and to protect patient safety.

EMAIL COMMUNICATIONS

Get LSTI Email Communications straight to your inbox. Sign Up Here

Contact

  • 101 Gibraltar Road, Suite 100 Horsham, PA 19044
  • 215-675-1800 (option 3)
  • info@lifesciencetraininginstitute.com

Course Categories

  • Clinical Trials (GCP Training)
  • Coronavirus / COVID-19
  • Introductory Pharma Courses
  • IT & Data Integrity for Pharma
  • Leadership & Training
  • Live Webinars
  • Manufacturing (GMP)
  • Medical Device Training
  • On-Demand Courses
  • Quality
  • Regulatory & Compliance
  • Research & Development
  • Special Packages

Meet Our Instructors

Footer logo
Copyright © 1996 - 2020 VertMarkets, Inc. All Rights Reserved.
  • Webinars
  • Custom Training
  • About LSTI
  • Privacy
  • Terms
Search
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok